Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma.
Tempora P, D'Amico S, Gragera P, Damiani V, Krol K, Scaldaferri V, Pandey K, Chung S, Lucarini V, Giorda E, Scarsella M, Volpe G, Pezzullo M, De Stefanis C, D'Oria V, De Angelis L, Giovannoni R, De Ioris MA, Melaiu O, Purcell AW, Locatelli F, Fruci D. Tempora P, et al. Among authors: fruci d. J Exp Clin Cancer Res. 2024 Oct 22;43(1):292. doi: 10.1186/s13046-024-03180-y. J Exp Clin Cancer Res. 2024. PMID: 39438988 Free PMC article.
Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma.
Lucarini V, Melaiu O, D'Amico S, Pastorino F, Tempora P, Scarsella M, Pezzullo M, De Ninno A, D'Oria V, Cilli M, Emionite L, Infante P, Di Marcotullio L, De Ioris MA, Barillari G, Alaggio R, Businaro L, Ponzoni M, Locatelli F, Fruci D. Lucarini V, et al. Among authors: fruci d. J Exp Clin Cancer Res. 2022 Nov 17;41(1):326. doi: 10.1186/s13046-022-02525-9. J Exp Clin Cancer Res. 2022. PMID: 36397148 Free PMC article.
PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.
Melaiu O, Mina M, Chierici M, Boldrini R, Jurman G, Romania P, D'Alicandro V, Benedetti MC, Castellano A, Liu T, Furlanello C, Locatelli F, Fruci D. Melaiu O, et al. Among authors: fruci d, d alicandro v. Clin Cancer Res. 2017 Aug 1;23(15):4462-4472. doi: 10.1158/1078-0432.CCR-16-2601. Epub 2017 Mar 7. Clin Cancer Res. 2017. PMID: 28270499
84 results